CA1124178A - Nabilone granulation - Google Patents
Nabilone granulationInfo
- Publication number
- CA1124178A CA1124178A CA343,252A CA343252A CA1124178A CA 1124178 A CA1124178 A CA 1124178A CA 343252 A CA343252 A CA 343252A CA 1124178 A CA1124178 A CA 1124178A
- Authority
- CA
- Canada
- Prior art keywords
- nabilone
- ethanol
- granulation
- solution
- pvp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
Abstract
Abstract A solution of nabilone and PVP in anhydrous ethanol is used to granulate ethanol-insoluble pharma-ceutically-acceptable excipients such as starch.
Description
X-5076 -1~
Title NABILONE GRANULATION
Nabilone[trans-dl-1-hydroxy-3-(1',1'-dimethylheptyl)-6,6 dimethyl-6a,7,8,9,10,10a-hexahydrodibenzo[b,d]pyran-9-one] is encompassed within a group of useful intermediates prepared by Farenholtz, et al., J. AmO Chem. Soc., 88, 2079 (1966), 89, 5934 (19571 for the preparation of ~9-THC (tetrahydrocannabinol) and its alkylated congeners having alkyl groups of from 1 to 10 carbon atoms at C-3. (~9-THC is trans-dl-l-hydroxy 3 n-pentyl-6,6,9~-trimethyl~-6a,7,8, lOa- tetrahydrodibenzo-[b,d]pyran). Archer, U.S. Patents No. 3,928,598, 3,953,603, 3,9446,673, and 3,98~,188 disclosed tha~ nabilone, in addition to beiny a "useful in-termediary", had activity as an ant.i-depressant, anti-anxiety, analgesic and/or sedative drug, and Archer and Lemberger further extencled its useful actions tv that of anti-emetic and for the treatment of g1aucoma, U.S. Patents ~o. 4,087,545 and 4,087,547.
Nabilone is not well absorbed from the ir.testine upon oral administration. Thakker, et al., J.
Pharm. Pharmac., 29, 783 ~1977~ describe some useful formulations for nabilone including a dispersion in polyvinylpyrrolidinone. Thakker, et al~ mix nabilone with PVP in a ratio of 1:2-20 in a solvent such as ethanol and then remove the solvent by evaporation in vacuo. The product thus obtained is a ylassy solid which must first be broken up and then reduced to a fine powder in order to disperse it uniformlY in other pharmaceutical excipients prior to filling into telescoping gelatin capsules.
This invention is a process to provide a granulation formulation for nabilone which avoids the inconvenience and difficulties of the aforesaid Thakk~r et al solid dispersion.
Specifically the invention provides a solution of nabilone and polyvinylpyrrolidone in ethanol as a granulating solution. This solution is then used to granulate pharmaceutical excipients and carriers such - as starch, lactose, cellulose and the like. After drying and grinding, the powdered granular material is : suitable for blending with other materials to make a formulation suitable for filling into telescoping gelatin capsules as provided. In other words, the nabilone-PVP dispersion of Thakker et al. (loc. cit.) is formed in situ as a granulation for excipients which are insoluble in ethanol. The ratio of nabilone to PVP
contains, in the novel granulation as in the Thakker et - 20 al. dispersions, one par~ of nabilone to 2 to 20 parts of PVP.
A granulation thus prepared is shown to have excellent s~ability as regards nabilone, and dissolution data has shown that the granulation is equivalent to the Thakkex et al. dispersion prepared as a glas~ in the rotary evaporator and then powdered.
Equivalent bioavailability has been demonstrated in doss fox the granulation of th~s invention as compared with the Thakker et al. dispersion.
Other nabilone dispersions prepared by Thakker, et al., including one in polyethylene glycol, ~-5076 -3-can be prepared similarly in situ on the particularexcipient using our novel process as described for the nabilone-PVP dispersion abo~e; solution in ethanol followed by yranulation of an ethanol~insoluble excipi-ent.
This invention is further illustrated by the following specifi.c example.
Example 1 Five gram~ of nabilone were dissolved in 125 ml. of anhydrous ethanol .45 g. of polyvinylpyr-rolidone (PVP) were dissolved therein. The resulting viscous solution was added to 450 g. of starch flowable powder in a Hohart mixer. A small amount of additional anhydrous ethanol was used to rinse the nabilone-PVP
solution into the mixer. After thorough mixing, the granulation was wet screened through a no. 4 screen (a no. 6 screen can also be used). The screened granula-tion was air dried and then ground to the desired size in a ball mill.
A nabilone-PVP-starch granula~ion so prepared can be further blended with other excipients to give a final mixture having the desirad nabilone concentration ~or loading into empty telescoping gelatin capsules.
Other ethanol insoluble excipients such as lactose, mannitol and dextrose can be used in place of flowable ~tarch in preparing the above granula-tion.
. .
Title NABILONE GRANULATION
Nabilone[trans-dl-1-hydroxy-3-(1',1'-dimethylheptyl)-6,6 dimethyl-6a,7,8,9,10,10a-hexahydrodibenzo[b,d]pyran-9-one] is encompassed within a group of useful intermediates prepared by Farenholtz, et al., J. AmO Chem. Soc., 88, 2079 (1966), 89, 5934 (19571 for the preparation of ~9-THC (tetrahydrocannabinol) and its alkylated congeners having alkyl groups of from 1 to 10 carbon atoms at C-3. (~9-THC is trans-dl-l-hydroxy 3 n-pentyl-6,6,9~-trimethyl~-6a,7,8, lOa- tetrahydrodibenzo-[b,d]pyran). Archer, U.S. Patents No. 3,928,598, 3,953,603, 3,9446,673, and 3,98~,188 disclosed tha~ nabilone, in addition to beiny a "useful in-termediary", had activity as an ant.i-depressant, anti-anxiety, analgesic and/or sedative drug, and Archer and Lemberger further extencled its useful actions tv that of anti-emetic and for the treatment of g1aucoma, U.S. Patents ~o. 4,087,545 and 4,087,547.
Nabilone is not well absorbed from the ir.testine upon oral administration. Thakker, et al., J.
Pharm. Pharmac., 29, 783 ~1977~ describe some useful formulations for nabilone including a dispersion in polyvinylpyrrolidinone. Thakker, et al~ mix nabilone with PVP in a ratio of 1:2-20 in a solvent such as ethanol and then remove the solvent by evaporation in vacuo. The product thus obtained is a ylassy solid which must first be broken up and then reduced to a fine powder in order to disperse it uniformlY in other pharmaceutical excipients prior to filling into telescoping gelatin capsules.
This invention is a process to provide a granulation formulation for nabilone which avoids the inconvenience and difficulties of the aforesaid Thakk~r et al solid dispersion.
Specifically the invention provides a solution of nabilone and polyvinylpyrrolidone in ethanol as a granulating solution. This solution is then used to granulate pharmaceutical excipients and carriers such - as starch, lactose, cellulose and the like. After drying and grinding, the powdered granular material is : suitable for blending with other materials to make a formulation suitable for filling into telescoping gelatin capsules as provided. In other words, the nabilone-PVP dispersion of Thakker et al. (loc. cit.) is formed in situ as a granulation for excipients which are insoluble in ethanol. The ratio of nabilone to PVP
contains, in the novel granulation as in the Thakker et - 20 al. dispersions, one par~ of nabilone to 2 to 20 parts of PVP.
A granulation thus prepared is shown to have excellent s~ability as regards nabilone, and dissolution data has shown that the granulation is equivalent to the Thakkex et al. dispersion prepared as a glas~ in the rotary evaporator and then powdered.
Equivalent bioavailability has been demonstrated in doss fox the granulation of th~s invention as compared with the Thakker et al. dispersion.
Other nabilone dispersions prepared by Thakker, et al., including one in polyethylene glycol, ~-5076 -3-can be prepared similarly in situ on the particularexcipient using our novel process as described for the nabilone-PVP dispersion abo~e; solution in ethanol followed by yranulation of an ethanol~insoluble excipi-ent.
This invention is further illustrated by the following specifi.c example.
Example 1 Five gram~ of nabilone were dissolved in 125 ml. of anhydrous ethanol .45 g. of polyvinylpyr-rolidone (PVP) were dissolved therein. The resulting viscous solution was added to 450 g. of starch flowable powder in a Hohart mixer. A small amount of additional anhydrous ethanol was used to rinse the nabilone-PVP
solution into the mixer. After thorough mixing, the granulation was wet screened through a no. 4 screen (a no. 6 screen can also be used). The screened granula-tion was air dried and then ground to the desired size in a ball mill.
A nabilone-PVP-starch granula~ion so prepared can be further blended with other excipients to give a final mixture having the desirad nabilone concentration ~or loading into empty telescoping gelatin capsules.
Other ethanol insoluble excipients such as lactose, mannitol and dextrose can be used in place of flowable ~tarch in preparing the above granula-tion.
. .
Claims (2)
1. A process which formulates nabilone for oral administration to mammals which comprises dissolv-ing nabilone and polyvinylpyrrolidone or polyethylene glycol in anhydrous ethanol and using the thus-formed viscous solution to granulate a pharmaceutically-accepta-ble ethanol-insoluble excipient by thoroughly mixing the solution with the excipient, and then drying the thus-formed granulation.
2. A process of claim 1 which comprises dis-solving polyvinylpyrrolidone and nabilone in ethanol to form the granulating solution.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19,810 | 1979-03-09 | ||
US06/019,810 US4195078A (en) | 1979-03-09 | 1979-03-09 | Nabilone granulation |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1124178A true CA1124178A (en) | 1982-05-25 |
Family
ID=21795156
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA343,252A Expired CA1124178A (en) | 1979-03-09 | 1980-01-08 | Nabilone granulation |
Country Status (16)
Country | Link |
---|---|
US (1) | US4195078A (en) |
EP (1) | EP0015635A1 (en) |
JP (1) | JPS55133309A (en) |
AU (1) | AU531805B2 (en) |
BE (1) | BE881049A (en) |
CA (1) | CA1124178A (en) |
CH (1) | CH643840A5 (en) |
DK (1) | DK8080A (en) |
FR (1) | FR2450606A1 (en) |
GB (1) | GB2045080B (en) |
IE (1) | IE49243B1 (en) |
IL (1) | IL59098A (en) |
IT (1) | IT1193886B (en) |
LU (1) | LU82072A1 (en) |
NZ (1) | NZ192557A (en) |
ZA (1) | ZA80104B (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4327080A (en) * | 1981-07-13 | 1982-04-27 | E. R. Squibb & Sons, Inc. | Novel Bendroflumethiazide formulations and method |
JPS59155309A (en) * | 1983-02-22 | 1984-09-04 | Teijin Ltd | Active type vitamin d3 composition and its preparation |
NZ211545A (en) * | 1984-04-11 | 1987-09-30 | Ici Australia Ltd | Composition having particulate trace element suspended in matrix of solid polyethylene glycol |
US4747881A (en) * | 1985-02-05 | 1988-05-31 | Warner-Lambert Company | Ingestible aggregate and delivery system prepared therefrom |
US4818539A (en) * | 1985-02-05 | 1989-04-04 | Warner-Lambert Company | Ingestible aggregate and delivery system prepared therefrom |
US4851392A (en) * | 1985-02-05 | 1989-07-25 | Warner-Lambert Company | Ingestible aggregate and delivery system prepared therefrom |
US4790991A (en) * | 1985-02-05 | 1988-12-13 | Warner-Lambert Company | Ingestible aggregate and delivery system prepared therefrom |
US4843098A (en) * | 1985-02-05 | 1989-06-27 | Warner-Lambert Company | Ingestible aggregate and delivery system prepared therefrom |
US4844908A (en) * | 1986-11-27 | 1989-07-04 | Duphar International Research B.V. | Method of preparing tablets with clovoxamine fumarate and tablets thus prepared |
EP0547796A1 (en) * | 1991-12-17 | 1993-06-23 | Konica Corporation | Solid chemicals for processing silver halide photographic light-sensitive material |
US6566560B2 (en) | 1999-03-22 | 2003-05-20 | Immugen Pharmaceuticals, Inc. | Resorcinolic compounds |
WO2002026728A2 (en) * | 2000-09-28 | 2002-04-04 | Immugen Pharmaceuticals, Inc. | Antiviral methods and compounds |
US20020137802A1 (en) * | 2000-09-28 | 2002-09-26 | Travis Craig R. | Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation |
AU2003214226A1 (en) * | 2002-03-18 | 2003-10-08 | Immugen Pharmaceuticals, Inc. | Topical formulations of resorcinols and cannibinoids and methods of use |
CA2845443A1 (en) * | 2014-03-04 | 2015-09-04 | Pharmascience Inc. | Orally disintegrating tablet of nabilone and method of manufacturing |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR886435A (en) * | 1941-09-29 | 1943-10-14 | Advanced knitting needle | |
US3136692A (en) * | 1961-06-30 | 1964-06-09 | Strong Cobb Arner Inc | Effervescent composition containing polyvinylpyrrolidone |
DE1467792A1 (en) * | 1965-05-21 | 1968-12-12 | Brunnengraeber & Co Gmbh Dr Ch | Disintegrants for pharmaceutical pellets |
CA885974A (en) * | 1968-04-02 | 1971-11-16 | R. Telfer William | Ferrous fumarate capsule and preparation |
IL32673A (en) * | 1968-08-05 | 1973-11-28 | Ciba Geigy Ag | A granular material containing oily or liquid therapeutically usable furanosides and a process for its manufacture |
US3632778A (en) * | 1970-06-10 | 1972-01-04 | Hoffmann La Roche | Tablets containing l-dopa |
NL7112288A (en) * | 1970-09-16 | 1972-03-20 | ||
JPS5418330B2 (en) * | 1973-03-16 | 1979-07-06 | ||
US3851032A (en) * | 1973-04-23 | 1974-11-26 | Sterling Drug Inc | Process of preparing a solid fine crystalline paracetamol polymer complex composition |
US3864492A (en) * | 1973-08-01 | 1975-02-04 | Abbott Lab | Method of treating depression using 1,4{40 -dihydroxy-3-n-pentyl-6,6,9-trimethyl-6a,7,10,10a-tetra-hydrodibenzo{8 b,d{9 pyran |
US3953603A (en) * | 1973-11-05 | 1976-04-27 | Eli Lilly And Company | Hexahydro-dibenzo[b,d,]pyran-9-ones as psychotropic, particularly anti-depressant drugs |
US3944673A (en) * | 1973-11-05 | 1976-03-16 | Eli Lilly And Company | Hexahydro-dibenzo[b,d]pyran-9-ones as analgesic drugs |
US4024275A (en) * | 1973-11-05 | 1977-05-17 | Eli Lilly And Company | Method of reducing elevated blood pressure with dihydroxy-hexahydrodibenzo(b,d)pyrans |
US3987188A (en) * | 1973-11-05 | 1976-10-19 | Eli Lilly And Company | Hexahydro-dibenzo[b,d]pyran-9-ones as sedative drugs |
IE39678B1 (en) * | 1973-11-05 | 1978-12-06 | Lilly Co Eli | A polymorphic form of a dibenzopyranone |
US3920809A (en) * | 1973-11-05 | 1975-11-18 | Lilly Co Eli | Dibenzo(b,d)pyranone dispersions |
AT329556B (en) * | 1974-10-24 | 1976-05-25 | Lilly Co Eli | PROCESS FOR PRODUCING A NEW STABLE POLYMORPHIC CRYSTALLINE FORM OF 1-HYDROXY-3- (1 ', 1'-DIMETHYLHEPTYL) -6,6-DIMETHYL-6,6A, 7,8,10,10A-HEXAHYDRO-9H-DIBENZO ( B, D) PYRAN-9-ON |
US4143129A (en) * | 1975-10-11 | 1979-03-06 | Lilly Industries Limited | Cephalexin tablets |
US4087546A (en) * | 1976-02-17 | 1978-05-02 | Eli Lilly And Company | Hexahydro-dibenzo[b,d]pyran-9-ones as antiasthmatic drugs |
US4088777A (en) * | 1976-02-17 | 1978-05-09 | Eli Lilly And Company | Hexahydro-dibenzo[b,d]pyran-9-ones as anticonvulsant drugs |
US4087547A (en) * | 1976-02-17 | 1978-05-02 | Eli Lilly And Company | Hexahydro-dibenzo[b,d]pyran-9-ones in treatment of glaucoma |
US4087545A (en) * | 1976-02-17 | 1978-05-02 | Eli Lilly And Company | Hexahydro-dibenzo[b,d]pyran-9-ones as antiemetic drugs |
-
1979
- 1979-03-09 US US06/019,810 patent/US4195078A/en not_active Expired - Lifetime
-
1980
- 1980-01-08 ZA ZA00800104A patent/ZA80104B/en unknown
- 1980-01-08 CA CA343,252A patent/CA1124178A/en not_active Expired
- 1980-01-08 NZ NZ192557A patent/NZ192557A/en unknown
- 1980-01-08 DK DK8080A patent/DK8080A/en not_active Application Discontinuation
- 1980-01-09 IT IT19114/80A patent/IT1193886B/en active
- 1980-01-09 BE BE1/9675A patent/BE881049A/en not_active IP Right Cessation
- 1980-01-09 IL IL59098A patent/IL59098A/en not_active IP Right Cessation
- 1980-01-09 CH CH13880A patent/CH643840A5/en not_active IP Right Cessation
- 1980-01-09 FR FR8000430A patent/FR2450606A1/en active Granted
- 1980-01-10 EP EP80300094A patent/EP0015635A1/en not_active Ceased
- 1980-01-10 IE IE42/80A patent/IE49243B1/en not_active IP Right Cessation
- 1980-01-10 GB GB8000871A patent/GB2045080B/en not_active Expired
- 1980-01-10 LU LU82072A patent/LU82072A1/en unknown
- 1980-01-10 JP JP172880A patent/JPS55133309A/en active Granted
- 1980-01-11 AU AU54554/80A patent/AU531805B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
IT8019114A0 (en) | 1980-01-09 |
AU5455480A (en) | 1980-09-11 |
IL59098A (en) | 1983-09-30 |
ZA80104B (en) | 1981-08-26 |
GB2045080A (en) | 1980-10-29 |
BE881049A (en) | 1980-07-09 |
JPS55133309A (en) | 1980-10-17 |
JPH0142923B2 (en) | 1989-09-18 |
CH643840A5 (en) | 1984-06-29 |
EP0015635A1 (en) | 1980-09-17 |
US4195078A (en) | 1980-03-25 |
IE49243B1 (en) | 1985-09-04 |
GB2045080B (en) | 1983-05-25 |
FR2450606B1 (en) | 1983-04-15 |
NZ192557A (en) | 1981-05-01 |
LU82072A1 (en) | 1980-04-23 |
AU531805B2 (en) | 1983-09-08 |
IL59098A0 (en) | 1980-05-30 |
DK8080A (en) | 1980-09-10 |
IE800042L (en) | 1980-09-09 |
FR2450606A1 (en) | 1980-10-03 |
IT1193886B (en) | 1988-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1124178A (en) | Nabilone granulation | |
KR930007251B1 (en) | Process for preparing stable nicorandil preparation | |
CN110650730B (en) | Vitamin D analogue preparation and preparation method thereof | |
US4882144A (en) | Solid, rapidly released medicament preparations containing dihydropyridines, and processes for their preparation | |
RU2166936C2 (en) | Method of preparing dosing units by wet granulation method | |
EP1175205B1 (en) | Solid dispersion comprising ritonavir, fenofibrate or griseofulvin | |
KR100198017B1 (en) | Low dose dry pharmaceutical preparations | |
KR910001924B1 (en) | Process for preparing delayed releasing tube tablet | |
UA72925C2 (en) | Fenofibrate-containing pharmaceutical composition and method for its preparation (variants) | |
EP0411629A2 (en) | A process for micronizing slightly-soluble drug | |
KR100580855B1 (en) | Stabilized tibolone compositions | |
KR920006908B1 (en) | Process for preparing solid medicament preparation containing dihydropyridines | |
CN101219124A (en) | Hydrochloric acid cefetamet pivoxil dispersible tablet and method for preparing the same | |
US20020150618A1 (en) | Process for preparing solid dosage forms of very low-dose drugs | |
US5266581A (en) | Solid composition containing dihydropyridine, PVP and PVPP | |
JPS62228017A (en) | Manufacture of solid quick release drug composition containing dihydropyridine | |
JPH031288B2 (en) | ||
EP0735862B1 (en) | Method for dry blend compression of medicaments | |
US3920806A (en) | Growth promoting subcutaneous compositions | |
US4804540A (en) | Process for preparing the combination products of triamterene and hydrochlorothiazide | |
EP0381174B1 (en) | Process for the manufacture of solid pharmaceutical preparations | |
EA000740B1 (en) | Process for preparing solid dosage forms of very low-dose drugs and a pharmaceutical obtained therein | |
CN114344310B (en) | Pharmaceutical composition for treating gout and preparation method and application thereof | |
KR880001558B1 (en) | Processes for the production of solid rapidly released medicament preparations containing dihydropyridines | |
CN112190580A (en) | Method for preparing ezetimibe tablets and ezetimibe tablets |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |